13-May-2024
TipRanks (Mon, 13-May 10:30 PM ET)
Theravance Biopharma GAAP EPS of -$0.24 beats by $0.01, revenue of $14.51M beats by $0.56M
Seeking Alpha News (Mon, 13-May 4:19 PM ET)
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
PRNewswire (Mon, 13-May 4:05 PM ET)
Notable earnings after Monday's close
Seeking Alpha News (Sun, 12-May 5:35 PM ET)
Theravance Biopharma Q1 2024 Earnings Preview
Seeking Alpha News (Sun, 12-May 5:35 PM ET)
Theravance Biopharma to Participate in an Upcoming Investor Conference
PRNewswire (Thu, 9-May 6:00 AM ET)
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
PRNewswire (Mon, 29-Apr 6:00 AM ET)
PRNewswire (Wed, 10-Apr 6:00 AM ET)
PRNewswire (Mon, 26-Feb 4:05 PM ET)
PRNewswire (Wed, 14-Feb 6:00 AM ET)
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Theravance Biopharma - trades on the NASDAQ stock market under the symbol TBPH.
As of May 13, 2024, TBPH stock price climbed to $9.58 with 178,936 million shares trading.
TBPH has a beta of 0.36, meaning it tends to be less sensitive to market movements. TBPH has a correlation of 0.02 to the broad based SPY ETF.
TBPH has a market cap of $477.06 million. This is considered a Small Cap stock.
Last quarter Theravance Biopharma - reported $18 million in Revenue and -$.17 earnings per share. This fell short of revenue expectation by $-115,000 and missed earnings estimates by -$.02.
In the last 3 years, TBPH stock traded as high as $19.34 and as low as $6.10.
The top ETF exchange traded funds that TBPH belongs to (by Net Assets): IWM, VTI, VXF, IWN, VB.
TBPH stock has underperformed the market in the last year with a return of -16.5%, while SPY returned +27.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in TBPH shares. However, TBPH has outperformed the market in the last 3 month and 2 week periods, returning +11.7% and +5.0%, while SPY returned +4.3% and +2.5%, respectively. This indicates TBPH has been having a stronger performance recently.
TBPH support price is $9.10 and resistance is $9.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TBPH stock will trade within this expected range on the day.